# Viking Soars Alone as Obesity Complex Shrugs

> Viking Therapeutics jumps 26.5% after GLP-1 results while obesity peers barely move.
- Title: Viking Soars Alone as Obesity Complex Shrugs · 24/7 Wall St.
- Summary: Viking Therapeutics jumps 26.5% after GLP-1 results while obesity peers barely move. Viking Therapeutics surged 26.5% on strong GLP-1 maintenance data as…
- Keywords: viking therapeutics, glp-1, obesity complex, nasdaq:vktx, weight loss, pharmaceuticals, biotech, obesity treatment, Viking, Soars, Alone, Obesity
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/09/22/viking-soars-alone-as-obesity-complex-shrugs-at-strong-glp-1-results
- Author: Trey Thoelcke
- Published: 2026-09-22T17:20:27+00:00
- Read time: 1 min
- Topics: viking therapeutics, glp-1, obesity complex, nasdaq:vktx, weight loss, pharmaceuticals, biotech, obesity treatment
## Viking Therapeutics Surges
Viking Therapeutics traded at $38.08, a session gain of 26.5% on September 22, 2026, after releasing positive GLP-1 maintenance results.

> Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse
## Obesity Peers Barely Moved
Structure Therapeutics fell 0.7% extending a 47.4% year-to-date decline while Eli Lilly and Novo Nordisk showed minimal price action.

> Structure traded at $36.56, down 0.7% on the session, extending a 47.4% year-to-date decline
## GLP-1 Maintenance Study
Viking reported a randomized trial showing weekly induction dosing followed by monthly or every-other-week maintenance regimens.

> The company framed the data as validating multiple maintenance schedules, a commercially significant finding because patient adherence is a well-known weakness of injectable GLP-1s
## Prior Phase 2 Results
Previous trials showed up to 14.7% body weight reduction after 13 weekly doses with 80% of subjects reaching at least 10% weight loss.

> VENTURE showed up to 14.7% mean body weight reduction after 13 weekly subcutaneous doses; VENTURE-Oral delivered up to 12.2% at 13 weeks
## Obesity Complex Reaction
Eli Lilly added 1.1% to $1,177.43 while Novo Nordisk slipped 0.7% to $39.54 amid list-price cuts effective January 2027.

> Novo Nordisk slipped 0.7% to $39.54, deepening a 32.5% one-year decline as the company works through list-price cuts of about 50% for Wegovy and 35% for Ozempic effective January 1, 2027
## Buyout Case Strengthens
Viking’s strong data hardens its standalone position with $502 million cash and fully enrolled Phase 3 trials.

> Strong data cuts both ways. It hardens Viking’s standalone posture, which already includes $502 million in cash at quarter end and both VANQUISH-1 and VANQUISH-2 fully enrolled
## Next Steps for Viking
Oral VK2735 Phase 3 trials expected in Q4 2026 with 78-week VANQUISH results to follow.

> Lian has said oral VK2735 Phase 3 initiation is expected in Q4 2026, positioning it to potentially become the first orally available dual GLP-1/GIP agonist to reach market
## Key takeaway

Viking Therapeutics surged 26.5% on strong GLP-1 maintenance data as obesity peers showed minimal reaction.